The high throughput screening hts market has seen considerable growth due to a variety of factors.
• In recent times, the size of the high throughput screening (HTS) market has expanded significantly. The market is projected to increase from $22.98 billion in 2024 to $25.49 billion in 2025, marking a compound annual growth rate (CAGR) of 10.9%.
The expansion in the previous period is a result of the growing uptake of high-throughput screening, a boost in research & development expenditure, augmented funding for research, an increase in healthcare spending, and a competitive marketplace.
The high throughput screening hts market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of high throughput screening (HTS) is anticipated to experience significant expansion in the coming years, with projections placing it at $36 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%.
Factors contributing to the growth during the forecast period include the expansion and growth rate of the market itself, strategic maneuvers by leading market players, increasing necessity for disease monitoring and drug discovery, escalating occurrence of chronic illnesses, and an increasing emphasis on the application of ultra high throughput screening (UHTS) techniques. Expected trends in the forecast period include progress in high-throughput screening technology and increased attention towards the adoption of ultra high throughput screening (UHTS) techniques.
Anticipated growth in the high-throughput screening (HTS) market is linked to the increasing incidence of chronic ailments. Chronic diseases are defined as lasting health conditions or illnesses that persist for a considerable duration, generally three months or more. HTS is crucial for rapidly examining a wide array of chemical compounds to identify potential drug candidates that target specific pathways or mechanisms involved in chronic diseases, which is critical for effective long-term disease management. For example, the National Library of Medicine, a US government organization, forecasted in January 2023 that the number of people aged 50 and over in the US with at least one chronic condition would escalate to 142.66 million by 2050. Consequently, the escalating prevalence of chronic diseases is projected to stimulate the expansion of the high-throughput screening (HTS) market.
The high throughput screening (HTS) market covered in this report is segmented –
1) By Products And Services: Consumables And Reagents, Instruments, Software And Services
2) By Technology: Ultra-High-Throughput Screening, Cell-Based Assays, Lab-On-A-Chip, Label-Free Technology
3) By Application: Target Identification And Validation, Primary And Secondary Screening, Toxicology Assessment, Other Applications
4) By End User: Pharmaceuticals And Biotechnology Industry, Academics And Research Institute, Contract Research Organization, Other End Users
Subsegments:
1) By Consumables And Reagents: Assay Plates, Reagents And Assay Kits, Sample Preparation Kits, Detection Reagents
2) By Instruments: Automated Liquid Handlers, Plate Readers, Robotics And Automation Systems, Microfluidic Devices
3) By Software And Services: Data Analysis Software, HTS Management Software, Consulting Services, Maintenance And Support Services
Leading companies in the high-throughput screening market are creating cutting-edge products like multimode plate readers to provide their clientele with superior and enhanced features. A multimode plate reader (MPR) is a modern lab equipment utilized for high-throughput screening, conducting assessments of chemical and biological samples in microplates by encompassing multiple detection modes for different assays in a singular platform. For example, in February 2023, the US-based MedTech firm, PerkinElmer Inc., introduced the EnVision Nexus system. This system is recognized to be the quickest and most sensitive multimode plate reader in existence. It's specifically engineered for rigorous high-throughput screening (HTS) applications to accelerate drugs discovery processes. The device presents its unique technology, with features such as dual detectors and optimized reagents like exclusive HTRF and AlphaLISA, along with the most recent reagent kits. It provides researchers an unequalled assay versatility, speed, accuracy, and sensitivity. Featuring convenience options like a plate stacker for either 20 or 50 plates, along with total automation for uninterrupted 24/7 workflow-oriented operations, the EnVision Nexus system enables researchers to effectively scrutinize millions of samples with exceptional efficacy.
Major companies operating in the high throughput screening (HTS) market are:
• Thermo Fisher Scientific Inc.
• AstraZeneca Plc
• Danaher Corporation
• Merck Group
• GE HealthCare Technologies Inc.
• Corning Inc.
• Agilent Technologies Inc.
• Lonza Group Ltd.
• Charles River Laboratories International Inc
• Beckman Coulter Inc.
• PerkinElmer Inc.
• Bio-Rad Laboratories
• Tecan Group Ltd.
• Sygnature Discovery Ltd.
• Luminex Corporation
• Hamilton Company
• Crown Bioscience Inc.
• HighRes Biosolutions
• NanoTemper Technologies GmbH
• BMG LABTECH GmbH
• Axxam SpA
• Reprocell Inc.
• BioTek Instruments Inc
• Aurora Biomed Inc.
• Cyclica Inc.
• Biomat Srl
• Diana Biotechnologies s.r.o
North America was the largest region in the high throughput screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.